• 1
    Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582592.
  • 2
    Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263383.
  • 3
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661662.
  • 4
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2012; 57: 167185.
  • 5
    Chang TT, Lai CL, Kew Yoon SK, Lee SS, Coelho HS, Carrilho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422430.
  • 6
    Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 15031514.
  • 7
    Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, et al. No resistance to tenofovirdisoproxilfumarate detected after upto 144 weeks of therapy in patients monoinfected with chronic hepatitisB virus. Hepatology 2011; 53: 763773.
  • 8
    Marcellin P, Buti M, Gane EJ, Krastev Z, Flisiak R, Germanidis G, et al. Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis [Abstract 1375]. Hepatology 2011; 54( suppl 1): 1011A1012A.
  • 9
    Lampertico P, Liaw YF. New perspectives in the therapy of chronic hepatitis B. Gut 2012; 61( suppl 1): i18i24
  • 10
    Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology; doi: 10.1002/hep.26180.
  • 11
    Aghemo A, Lampertico P, Colombo M. Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense. J Hepatol 2012; 57: 13261335.
  • 12
    Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011; 54: 91100.
  • 13
    Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 6272.
  • 14
    Lampertico P, Soffredini R, Viganò M, Yurdaydin C, Idilman R, Papatheodoridis GV, et al. Tenofovir monotherapy suppressed viral replication in most field practice, treatment-naïve patients with CHB followed for 3 years in a multicenter European study [Abstract 401]. Hepatology 2012; 56( suppl 1): 389A.